Next Article in Journal
5-((4-(-Phenyldiazenyl)phenyl)diazenyl)quinolin-8-ol
Next Article in Special Issue
4-(4-(2-Bromoethyl)phenoxy)-2,3,5,6-tetrafluoropyridine
Previous Article in Journal
(2S,2’S,4R,5S,5’R)-2,2’-Di-tert-butyl-4-hydroxy-5,5’-dimethyl-4,5’-bi(1,3-dioxolanyl)-4’-one
Previous Article in Special Issue
3-(4-(Benzyloxy)-3-methoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

4-(2,5-Dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine

by
Natalia V. Obruchnikova
and
Oleg A. Rakitin
*
N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospekt, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(3), M1700; https://doi.org/10.3390/M1700
Submission received: 31 May 2023 / Revised: 10 July 2023 / Accepted: 17 July 2023 / Published: 20 July 2023
(This article belongs to the Collection Heterocycle Reactions)

Abstract

:
1,2,5-Oxadiazol-3-amines with a heterocyclic substituent in the 4-position are being intensively investigated as compounds with valuable pharmacological activity. In this communication, the reaction of 1,2,5-oxadiazole-3,4-diamine with 2,5-hexanedione was shown to selectively give 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine as a product of the Paal–Knorr reaction. The structure of the synthesized compound was established by elemental analysis, high-resolution mass spectrometry, 1H and 13C NMR, and IR spectroscopy.

1. Introduction

1,2,5-Oxadiazoles (furazans) are an important class of heterocyclic compounds that exhibit various forms of biological activity [1]. Of greatest interest among these heterocycles are 3-aminofurazans and especially the commercially available 1,2,5-oxadiazole-3,4-diamine 1 (CAS 17220-38-1), which is the starting material for the synthesis of compounds with biological activity [2] and components of powerful energy compositions [3]. One of the most studied reactions for ortho-substituted aromatic and heterocyclic amines is the reaction with diketo derivatives, which leads to various polycyclic compounds. Treatment of 1,2,5-oxadiazole-3,4-diamine 1 with α-diketones gave 4a,5,9a,10-tetrahydro-4H,9H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b][1,2,5]oxadiazolo[3,4-e]pyrazine 2 (R = H) [4] or [1,2,5]oxadiazolo[3,4-b]pyrazines 3 (R = Alk, Ar) [5,6], and with β-diketones led to 4H-[1,2,5]oxadiazolo[3,4-b][1,4]diazepines 4 [7] (Scheme 1). Other diketo derivatives in the reaction with 1,2,5-oxadiazole-3,4-diamine have not been previously studied. Meanwhile, it is difficult to predict the course of reaction for various diketo derivatives, and the reaction products may be of interest as biologically active compounds. Herein, we report the study of the reaction between 1,2,5-oxadiazole-3,4-diamine 1 and 2,5-hexanedione and the synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine 5.

2. Results and Discussion

Treatment of 1,2,5-oxadiazole-3,4-diamine 1 with 1.1 equivalents of 2,5-hexanedione in AcOH gave a new product 5 (Scheme 2). When the reaction was carried out at room temperature, the starting compound 1 did not disappear within 10 h. Heating the mixture to 40–45 °C accelerated the reaction, which was completed within two hours with the formation of compound 5. According to the HRMS, elemental analysis, and 1H and 13C NMR data (Supplementary Materials), compound 5 is formally the product of the addition of 2,5-hexanedione and elimination of two H2O molecules. The 1H spectra of compound 5 showed the presence of two methyl groups (2.13 ppm), two identical C-H groups (5.98 ppm), and a broad signal (4.17 ppm) that can be attributed to the amino group. The IR spectrum had characteristic bands for the NH2 group (3409, 3328, 3255 and 3211 cm−1). The presence of five signals in the 13C NMR spectrum of compound 5 makes it possible to reject the symmetrical structure of (5Z,7Z)-5,8-dimethyl-4,9-dihydro-[1,2,5]oxadiazolo[3,4-b][1,4]diazocine 6, which should contain four signals in the 13C NMR spectrum. Thus, the spectral data unambiguously confirm the structure of compound 5 as a Paal–Knorr reaction product of 1,2,5-oxadiazole-3,4-diamine 1 at one amino group. When a mixture of one equiv. of compound 1 was refluxed in AcOH with four equiv. of 2,5-hexanedione, compound 5 was formed, and then gradually decomposed with the formation of a mixture of products, from which we were unable to isolate individual compounds including 3,4-bis(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazole. It is known that the reaction of ortho-phenylenediamine with 2,5-hexanedione leads to mono- and bis-pyrrole products of the Paal–Knorr reaction [8,9].
In conclusion, the selective synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine 5 was developed in the reaction of 1,2,5-oxadiazole-3,4-diamine 1 with 2,5-hexanedione in AcOH. 1,2,5-Oxadiazoles containing a pyrrole group at position 3 are known to exhibit antiproliferative activity in the sea urchin embryo model and in cultured human cancer cell lines [10,11]. In addition, many 1,2,5-oxadiazole-3-amines with a heterocyclic substituent at position 4 are known to have valuable pharmacological activity, see, for example, references [12,13,14,15,16]. Therefore, compound 5 may also have useful pharmacological properties.

3. Materials and Methods

The solvents and reagents were purchased from commercial sources and used as received. Elemental analysis was performed on a 2400 Elemental Analyzer (Perkin Elmer Inc., Waltham, MA, USA). Melting point was determined on a Kofler hot-stage apparatus and is uncorrected. 1H and 13C NMR spectra were taken with a Bruker AM-300 machine (Bruker AXS Handheld Inc., Kennewick, WA, USA) at frequencies of 300 and 75 MHz, correspondingly. The high-resolution MS spectrum was measured using a Bruker micrOTOF II instrument (Bruker Daltonik Gmbh, Bremen, Germany) with electrospray ionization (ESI). The IR spectrum was measured with a Bruker “Alpha-T” instrument in KBr pellet.
Synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine 5 (Supplementary Materials).
2,5-Hexanedione (0.51 mL, 4.4 mmol) was added to a solution of 1,2,5-oxadiazole-3,4-diamine (400 mg, 4 mmol) in AcOH (5 mL). The reaction mixture was stirred for 2 h at 40–45 °C, and then cooled to room temperature. Water (40 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO4, and the solvent was evaporated under reduced pressure. The solvent was removed and the residue was purified by column chromatography on silica gel (Silica gel Merck 60, eluent hexane/EtOAc, 10:1, v/v). Yield 510 mg (72%), colorless solid. Mp = 93–94 °C. IR spectrum (KBr), ν, cm−1: 3409, 3328, 3255, and 3211 (NH2), 2952, 2927 (C-H), 1646 (C=N), 1557, 1428, 1382, 1067, 989, 851, 778, 583. 1H NMR (CDCl3, ppm): δ 5.98 (2H, s, CH), 4.17 (2H, br s, NH2), 2.13 (6H, s, CH3). 13C NMR (CDCl3, ppm): 153.1 (C-N), 144.5 (C-N), 129.5 (C-CH3), 108.8 (CH), 12.1 (CH3). HRMS (ESI-TOF), m/z: calcd for C8H11N4O [M + H]+ 179.0927. Found, 179.0930. Anal. calcd for C8H10N4O: C, 53.91; H, 5.66; N, 31.45. Found: C, 53.87; H, 5.61; N, 31.39%.

Supplementary Materials

The following are available online: copies of 1H, 13C NMR, IR, and HR mass-spectra for the compound 5.

Author Contributions

Conceptualization, N.V.O.; methodology, O.A.R.; software, N.V.O.; validation, O.A.R.; formal analysis, investigation, N.V.O.; resources, O.A.R.; data curation, O.A.R.; writing—original draft preparation, O.A.R.; writing—review and editing, O.A.R.; visualization, O.A.R.; supervision, O.A.R.; project administration, O.A.R.; funding acquisition, O.A.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of compound 5 are available from the authors.

References

  1. Makhova, N.N.; Fershtat, L.L. 1,2,5-Oxadiazoles. In Comprehensive Heterocyclic Chemistry IV; Elsevier: Amsterdam, The Netherlands, 2022; pp. 190–251. [Google Scholar] [CrossRef]
  2. Sheremetev, A.B.; Makhova, N.N.; Friedrichsen, W. Monocyclic furazans and furoxans. Adv. Heterocycl. Chem. 2001, 78, 65–188. [Google Scholar] [CrossRef]
  3. Fershtat, L.L.; Makhova, N.N. 1,2,5-Oxadiazole-Based High-Energy-Density Materials: Synthesis and Performance. Chempluschem 2020, 85, 13–42. [Google Scholar] [CrossRef] [Green Version]
  4. Willer, R.L.; Moore, D.W. Synthesis and chemistry of some furazano- and furoxano[3,4-b]piperazines. J. Org. Chem. 1985, 50, 5123–5127. [Google Scholar] [CrossRef]
  5. Gasco, A.; Ruà, G.; Menziani, E.; Nano, G.M.; Tappi, G. Studies in the chemistry of 1,2,5-oxadiazole. I. Synthesis of some furazanopyrazines from 3,4-diamino-1,2,5-oxadiazole. J. Heterocycl. Chem. 1969, 6, 769–770. [Google Scholar] [CrossRef]
  6. Ignat’Ev, N.V.; Schulte, M.; Koppe, K.; Barthen, P.; Zlotin, S.G.; Makhova, N.N.; Sheremetev, A.B.; Valente, A.A. Ionic Liquids—Advanced Reaction Media for Organic Synthesis. Phosphorus Sulfur Silicon Relat. Elem. 2011, 186, 1205–1216. [Google Scholar] [CrossRef]
  7. Gasco, A.; Ruá, G.; Menziani, E.; Nano, G.M.; Tappi, G. Studies in the chemistry of 1,2,5-oxadiazole (II). Synthesis and properties of furazanodiazepines. J. Heterocycl. Chem. 1970, 7, 131–133. [Google Scholar] [CrossRef]
  8. Guo, L.; Zhou, M.; Guo, H.; Xu, W.; Li, Z. Dilithium complex incorporating phenyl bridged neutral pyrrolyl-arylamide ligand: Synthesis, characterization, reaction, and catalytic activity. Inorg. Chem. Commun. 2020, 119, 108036. [Google Scholar] [CrossRef]
  9. Akbaşlar, D.; Demirkol, O.; Giray, S. Paal–Knorr Pyrrole Synthesis in Water. Synth. Commun. 2014, 44, 1323–1332. [Google Scholar] [CrossRef]
  10. Stepanov, A.I.; Astrat’Ev, A.A.; Sheremetev, A.B.; Lagutina, N.K.; Palysaeva, N.V.; Tyurin, A.Y.; Aleksandrova, N.S.; Sadchikova, N.P.; Suponitsky, K.Y.; Atamanenko, O.P.; et al. A facile synthesis and microtubule-destabilizing properties of 4-(1H-benzo[d]imidazol-2-yl)-furazan-3-amines. Eur. J. Med. Chem. 2015, 94, 237–251. [Google Scholar] [CrossRef] [PubMed]
  11. Kulikov, A.S.; Epishina, M.A.; Batog, L.V.; Rozhkov, V.Y.; Makhova, N.N.; Konyushkin, L.D.; Semenova, M.N.; Semenov, V.V. Synthesis and antineoplastic properties of (1H-1,2,3-triazol-1-yl)furazans. Russ. Chem. Bull. 2013, 62, 836–843. [Google Scholar] [CrossRef] [PubMed]
  12. Li, Q.; Chen, Y.; Xing, S.; Liao, Q.; Xiong, B.; Wang, Y.; Lu, W.; He, S.; Feng, F.; Liu, W.; et al. Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection. J. Med. Chem. 2021, 64, 6856–6876. [Google Scholar] [CrossRef]
  13. Wlodarchak, N.; Teachout, N.; Beczkiewicz, J.; Procknow, R.; Schaenzer, A.J.; Satyshur, K.; Pavelka, M.; Zuercher, W.; Drewry, D.; Sauer, J.-D.; et al. In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams to Inhibit Mycobacterial Growth. Mol. Pharm. 2018, 15, 5410–5426. [Google Scholar] [CrossRef]
  14. Schaenzer, A.J.; Wlodarchak, N.; Drewry, D.H.; Zuercher, W.J.; Rose, W.E.; Striker, R.; Sauer, J.-D. A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA. J. Biol. Chem. 2017, 292, 17037–17045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Pyrkov, T.V.; Sevostyanova, I.A.; Schmalhausen, E.V.; Shkoporov, A.N.; Vinnik, A.A.; Muronetz, V.I.; Severin, F.F.; Fedichev, P.O. Structure-Based Design of Small-Molecule Ligands of Phosphofructokinase-2 Activating or Inhibiting Glycolysis. ChemMedChem 2013, 8, 1322–1329. [Google Scholar] [CrossRef] [PubMed]
  16. Bandarage, U.; Hare, B.; Parsons, J.; Pham, L.; Marhefka, C.; Bemis, G.; Tang, Q.; Moody, C.S.; Rodems, S.; Shah, S.; et al. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors. Bioorganic Med. Chem. Lett. 2009, 19, 5191–5194. [Google Scholar] [CrossRef] [PubMed]
Scheme 1. Reaction of 1,2,5-oxadiazole-3,4-diamine 1 with α-diketones.
Scheme 1. Reaction of 1,2,5-oxadiazole-3,4-diamine 1 with α-diketones.
Molbank 2023 m1700 sch001
Scheme 2. Synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine 5.
Scheme 2. Synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine 5.
Molbank 2023 m1700 sch002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Obruchnikova, N.V.; Rakitin, O.A. 4-(2,5-Dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine. Molbank 2023, 2023, M1700. https://doi.org/10.3390/M1700

AMA Style

Obruchnikova NV, Rakitin OA. 4-(2,5-Dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine. Molbank. 2023; 2023(3):M1700. https://doi.org/10.3390/M1700

Chicago/Turabian Style

Obruchnikova, Natalia V., and Oleg A. Rakitin. 2023. "4-(2,5-Dimethyl-1H-pyrrol-1-yl)-1,2,5-oxadiazol-3-amine" Molbank 2023, no. 3: M1700. https://doi.org/10.3390/M1700

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop